Epilepsy — Clinical Documentation Guide (2026)

🔍 Definition

Epilepsy is a chronic neurological disorder characterized by recurrent, unprovoked seizures resulting from abnormal, excessive, or synchronous neuronal activity in the brain. Per the International League Against Epilepsy (ILAE) 2014 operational definition, a person is considered to have epilepsy if they meet one of the following criteria: (1) at least two unprovoked (or reflex) seizures occurring more than 24 hours apart; (2) one unprovoked seizure with a probability of further seizures similar to the general recurrence risk after two unprovoked seizures (≥60%) over the next 10 years; or (3) diagnosis of an epilepsy syndrome.

Key distinction for coders: A seizure is a discrete event (symptom); epilepsy is the underlying disorder. Febrile seizures (R56.0x) and provoked convulsions (R56.1, R56.9) are coded separately and do not, by themselves, constitute epilepsy. According to CDC epidemiological data, approximately 3.4 million people in the United States have active epilepsy, making accurate ICD-10-CM coding essential for risk adjustment, resource allocation, and quality reporting.

Intractable (drug-resistant) epilepsy is defined by the ILAE as failure of adequate trials of two tolerated and appropriately chosen antiepileptic drug (AED) schedules (whether as monotherapy or in combination) to achieve sustained seizure freedom. This distinction is critically important for ICD-10-CM code selection and risk adjustment, as intractable epilepsy codes carry a significantly higher HCC weight under CMS-HCC v28.

🗂️ Alternative Terminology

Epilepsy encompasses a broad spectrum of conditions. Clinicians may use varied terminology across specialties. The table below maps common clinical terms to formal ICD-10-CM language.

🩺 Signs & Symptoms

Clinical presentations vary significantly by seizure type, epilepsy syndrome, and localization. Accurate documentation of semiology (clinical features of the seizure) is essential for both coding specificity and clinical management.

Focal (Partial) Seizures

• Focal aware (simple partial): Motor (clonic jerking, tonic posturing), sensory (tingling, visual phenomena), autonomic (flushing, palpitations), or psychic (déjà vu, fear) symptoms with preserved consciousness. Duration typically 30–120 seconds.
• Focal impaired awareness (complex partial): Altered consciousness, automatisms (lip-smacking, picking, fumbling), post-ictal confusion. Often temporal or frontal lobe origin. Duration 1–3 minutes.
• Focal to bilateral tonic-clonic (secondarily generalized): Begins focally, spreads bilaterally; tonic phase followed by clonic phase; post-ictal Todd paralysis possible.

Generalized Seizures

• Absence (petit mal): Brief (5–30 sec) staring, eye fluttering, no post-ictal period; typical onset ages 4–10 (childhood absence) or adolescence (juvenile). 3 Hz spike-wave on EEG.
• Myoclonic: Sudden, brief muscle jerks; often bilateral proximal limbs; morning predominance in JME; preserved consciousness.
• Atonic (drop attacks): Sudden loss of muscle tone, falls, risk of injury; common in LGS.
• Tonic: Sustained muscle stiffening; often nocturnal; seen in LGS.
• Tonic-clonic (grand mal): Tonic phase (stiffening, cry, apnea) followed by clonic phase (rhythmic jerking); post-ictal confusion, lethargy; tongue biting, urinary incontinence.
• Epileptic spasms: Sudden flexion/extension of trunk and limbs in clusters; peak age 4–12 months; hypsarrhythmia on EEG (West syndrome).

Status Epilepticus

Defined operationally as seizure activity ≥5 minutes or two or more seizures without return to baseline. Clinical features include sustained convulsions, non-convulsive SE (NCSE — altered mental status, subtle motor signs), or refractory SE. Neurocritical Care Society guidelines define refractory SE as failure to respond to two first-line agents.

Syndrome-Specific Features

• Lennox-Gastaut (G40.81x): Triad of mixed seizure types (tonic, atonic, atypical absence), intellectual disability, slow spike-wave (<2.5 Hz) on EEG; onset ages 1–8.
• Dravet syndrome (G40.83x): SCN1A mutation; fever-sensitive prolonged febrile hemiconvulsions in first year of life; progressive cognitive decline; multiple seizure types.
• Juvenile myoclonic epilepsy (G40.B): Morning myoclonic jerks, generalized tonic-clonic seizures, absence; onset ages 12–18; photosensitivity; excellent AED response but lifelong treatment often required.

🧭 Differential Diagnosis

Accurate epilepsy coding requires confirmed diagnosis. Multiple conditions mimic seizures and require careful clinical differentiation. The American Academy of Neurology (AAN) recommends EEG and neuroimaging as part of the initial workup to confirm epilepsy diagnosis.

📋 Clinical Indicators for Coders/CDI

The following clinical indicators should be present in the medical record to support epilepsy coding. CDI specialists should review these elements and query if documentation is incomplete.

🦴 Anatomy & Pathophysiology

Epilepsy arises from an imbalance between excitatory (glutamatergic) and inhibitory (GABAergic) neurotransmission, leading to abnormal hypersynchronous neuronal firing. The specific pathophysiology varies by epilepsy type:

Focal Epilepsy

In localization-related epilepsy, a discrete cortical region — the epileptogenic zone — generates seizures. The temporal lobe (especially hippocampus and amygdala) is the most common site, often associated with hippocampal sclerosis (mesial temporal sclerosis). The frontal, parietal, and occipital lobes may also harbor epileptogenic foci from cortical dysplasia, prior infarct, tumor, or trauma. Ictal activity may remain focal (simple partial) or propagate along white matter tracts to involve wider networks (complex partial) or the entire cortex (secondarily generalized). Per ILAE 2017 classification, focal onset is further described as aware, impaired awareness, or unknown awareness.

Generalized Epilepsy

Generalized epilepsies involve widespread cortical and subcortical networks from seizure onset. The thalamocortical circuitry plays a central role — particularly in absence epilepsy, where 3 Hz spike-wave discharges arise from rhythmic thalamic oscillations and cortical spread. Idiopathic generalized epilepsies (IGE) are predominantly genetic (e.g., CACNA1A, GABRA1, SCN1A mutations), while symptomatic generalized epilepsies (e.g., LGS) involve diffuse cortical pathology.

Syndrome-Specific Pathophysiology

• Dravet syndrome: Loss-of-function mutations in SCN1A (Nav1.1 sodium channel) predominantly affect GABAergic interneurons, leading to disinhibition and seizure susceptibility. Heat/fever-induced channel dysfunction explains the fever sensitivity.
• West syndrome (infantile spasms): Multiple etiologies (structural, metabolic, genetic); hypsarrhythmia on EEG represents severe cortical disorganization in a developing brain; ACTH/vigabatrin are first-line treatments targeting the abnormal infantile epileptic network.
• Lennox-Gastaut syndrome: Diffuse cortical pathology disrupts the slow sleep oscillation system; the tonic seizures arise from activation of the brainstem via the corticoreticular pathway.
• Lafora disease: Autosomal recessive mutation in EPM2A or NHLRC1; accumulation of polyglucosan (Lafora) bodies in neurons leads to progressive neurodegeneration with myoclonus, generalized seizures, and cognitive decline in adolescence.

Status Epilepticus Pathophysiology

Prolonged seizure activity leads to excitotoxic neuronal injury through calcium influx, mitochondrial dysfunction, and free radical production. GABA-A receptor internalization during SE reduces benzodiazepine efficacy over time, explaining the importance of early, aggressive treatment. Convulsive SE carries mortality risk of 10–40%; non-convulsive SE (NCSE) may be underdiagnosed and requires EEG confirmation per Neurocritical Care Society consensus.

💊 Medication Impact / Treatment

Antiepileptic drugs (AEDs) — also called anti-seizure medications (ASMs) — are the cornerstone of epilepsy management. AED selection is guided by seizure type, epilepsy syndrome, patient age, comorbidities, and tolerability. Approximately 65–70% of patients achieve seizure freedom on AEDs; those failing two appropriate AED trials are classified as drug-resistant (intractable).

First-Line AEDs by Seizure/Syndrome Type

• Focal epilepsy: Lacosamide, lamotrigine, levetiracetam, oxcarbazepine, carbamazepine (not preferred in generalized)
• Generalized tonic-clonic: Valproate, lamotrigine, levetiracetam, topiramate
• Absence: Ethosuximide (first-line for pure absence), valproate, lamotrigine
• Juvenile myoclonic: Valproate (most effective), levetiracetam, lamotrigine; avoid carbamazepine/phenytoin (may worsen)
• Dravet syndrome: Clobazam, valproate, stiripentol; fenfluramine (Fintepla) and cannabidiol (Epidiolex) FDA-approved for Dravet
• Lennox-Gastaut: Valproate, clobazam, lamotrigine; cannabidiol (Epidiolex), rufinamide, felbamate, clobazam FDA-approved add-ons
• Infantile spasms: ACTH (adrenocorticotropic hormone), vigabatrin (especially tuberous sclerosis), prednisolone
• Status epilepticus (acute): Benzodiazepines (lorazepam IV, diazepam rectal/IV, midazolam IM) → fosphenytoin/levetiracetam → anesthetic (propofol, midazolam drip, pentobarbital coma)

Long-Term AED Use — Z Code Coding

When a patient is on long-term AED therapy (not just acute use), code Z79.899 (long-term [current] use of other medication) as an additional code per FY2026 ICD-10-CM Official Guidelines Section I.C.21.c.3. Note: Z79.1 covers anticoagulants; Z79.899 is the appropriate code for anticonvulsants (AEDs) in FY2026, as no specific Z79 subcategory exists for AEDs.

Surgical & Device Therapies — Code Impact

When the patient has an implanted vagus nerve stimulator (VNS), use Z45.42 for encounters involving adjustment or management of the VNS device. For responsive neurostimulation (RNS/NeuroPace), the encounter may be coded with Z45.49 (encounter for adjustment/management of other implanted nervous system device). For a history of resective epilepsy surgery (lobectomy, hemispherectomy, callosotomy), document Z87.39. Corpus callosotomy and hemispherectomy may also be associated with Z98.89 (other specified postprocedural states).

Preview ends here. The full guide continues with FY2026 ICD-10-CM code sets, CPT surgical coding, MS-DRG mapping, reimbursement guidance, CDI query templates, and an audit checklist — all available to CCO Members.

← Back to All Clinical Documentation Guides